リウマチ性関節炎治療薬の世界市場

GBI Researchが発行した調査報告書(DATA1122035)
◆英語タイトル:Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
◆商品コード:DATA1122035
◆発行会社(リサーチ会社):GBI Research
◆発行日:2016年8月
◆ページ数:66
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD6,995 ⇒換算¥790,435見積依頼/購入/質問フォーム
Site LicenseUSD13,990 ⇒換算¥1,580,870見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD20,985 ⇒換算¥2,371,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Frontier Pharma: Rheumatoid Arthritis – Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
Summary

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

Scope

Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
– What is the pathophysiology of RA?
– Which products and therapeutic strategies dominate the clinical and commercial landscapes?
– What are the most significant unmet needs within the RA market?
Considerable diversification from current market trends is evident within the RA pipeline.
– Which molecular targets are most prominent within the pipeline?
– What proportion of pipeline products are first in class?
– Which first-in-class targets are most promising?
Deal values for licensing and co-development deals vary considerably.
– How many strategic consolidations have been completed in the past decade?
– Which types of assets attract the largest deal values?
– Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to –
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5
2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5
2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 10
4.3 Epidemiology 11
4.4 Etiology 11
4.5 Pathophysiology 11
4.6 Co-morbidities and Complications 12
4.7 Diagnosis 12
4.7.1 Blood Tests 12
4.7.2 1987 Rheumatoid Arthritis Classification 13
4.7.3 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 13
4.8 Disease Progression 13
4.9 Treatment Options and Treatment Algorithm 14
4.10 Overview of Marketed Products in Rheumatoid Arthritis 15
4.10.1 Molecule Type and Molecular Target Analysis 15
5 Assessment of Pipeline Product Innovation 17
5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target 17
5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family 21
5.3 First-in-Class Programs Targeting Novel Molecular Targets 21
6 Signaling Network, Disease Causation and Innovation Alignment 32
6.1 Complexity of Signaling Networks in Rheumatoid Arthritis 32
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 33
6.3 First-in-Class Matrix Assessment 33
7 First-in-Class Target Evaluation 37
7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40) 37
7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2) 38
7.3 Pipeline Programs Targeting IL-10 and IL-18 39
7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2) 41
7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7) 42
7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ) 43
7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5) 44
7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine 13 (CXCL13) 46
8 Strategic Consolidations 48
8.1 Industry-Wide First-in-Class Deals 48
8.2 Licensing Deals 49
8.3 Co-development Deals 52
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 56
9 Appendix 59
9.1 References 59
9.2 Abbreviations 63
9.3 Research Methodology 64
9.4 Secondary Research 64
9.4.1 Market Analysis 64
9.4.2 Pipeline Analysis 65
9.4.3 First-in-Class Matrix Assessment 65
9.4.4 First-in-Class Target Profiles 65
9.4.5 Licensing and Co-Development Deals 66
9.5 Contact Us 66
9.6 Disclaimer 66

1.1 List of Tables
Table 1: 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010 13
Table 2: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40), 2016 37
Table 3: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40), 2016 38
Table 4: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Tyrosine-Protein Kinase TYK2 (TYK2), 2016 39
Table 5: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Tyrosine-Protein Kinase TYK2 (TYK2), 2016 39
Table 6: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Interleukin 18, 2016 40
Table 7: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Interleukin 18, 2016 40
Table 8: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Interleukin 10, 2016 41
Table 9: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Interleukin 10, 2016 41
Table 10: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of 72 kDa type IV collagenase (MMP2), 2016 42
Table 11: Rheumatoid Arthritis, Global, Pipeline Programs Targeting 72 kDa type IV collagenase (MMP2), 2016 42
Table 12: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of P2X Purinoceptor 7 (P2RX7), 2016 43
Table 13: Rheumatoid Arthritis, Global, Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7), 2016 43
Table 14: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Protein Kinase C Theta Type (PRKCQ), 2016 44
Table 15: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ), 2016 44
Table 16: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4), 2016 45
Table 17: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 5 (CCL5), 2016 45
Table 18: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5), 2016 45
Table 19: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of C-X-C Motif Chemokine 10, 2016 46
Table 20: Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-X-C Motif Chemokine 10, 2016 47
Table 21: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of C-X-C Motif Chemokine 13, 2016 47
Table 22: Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-X-C Motif Chemokine 13 (CXCL13), 2016 47

1.2 List of Figures
Figure 1: Rheumatoid Arthritis, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2012 7
Figure 2: Rheumatoid Arthritis, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013 8
Figure 3: Rheumatoid Arthritis, Global, Marketed Products by Molecule Type and Molecular Target, 2016 16
Figure 4: Rheumatoid Arthritis, Global, Pipeline by Stage of Development and Molecule Type, 2016 18
Figure 5: Rheumatoid Arthritis, Global, Pipeline by Molecular Target and Stage of Development, 2016 19
Figure 6: Rheumatoid Arthritis, Global, Pipeline by Key Molecular Target Groups, 2016 20
Figure 7: Rheumatoid Arthritis, Global, Distribution of Molecular Targets Across Pipeline and Marketed Products, 2016 21
Figure 8: Rheumatoid Arthritis, Global, Distribution of Pipeline First-in-Class and Established Molecular Targets, 2016 22
Figure 9: Rheumatoid Arthritis, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Stage of Development (%), 2016 22
Figure 10: Rheumatoid Arthritis, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Molecular Target (%), 2016 22
Figure 11: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 1) 24
Figure 12: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 2) 25
Figure 13: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 3) 26
Figure 14: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 4) 27
Figure 15: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 5) 28
Figure 16: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 6) 29
Figure 17: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 7) 30
Figure 18: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 8) 31
Figure 19: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 1) 34
Figure 20: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 2) 35
Figure 21: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 3) 36
Figure 22: Rheumatoid Arthritis, Global, Industry-Wide Deals by Stage of Development, 2006-2014 48
Figure 23: Rheumatoid Arthritis, Global, Industry-Wide Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2014 49
Figure 24: Rheumatoid Arthritis, Global, Licensing Deals by Region and Deal Value ($m), 2006-2016 50
Figure 25: Rheumatoid Arthritis, Global, Disclosed and Undisclosed Licensing Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 50
Figure 26: Rheumatoid Arthritis, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 51
Figure 27: Rheumatoid Arthritis, Frequency and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, Global, 2006-2016 52
Figure 28: Rheumatoid Arthritis, Global, Co-development Deals by Region and Deal Value ($m), 2006-2016 53
Figure 29: Rheumatoid Arthritis, Global, Disclosed and Undisclosed Co-development Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015 53
Figure 30: Rheumatoid Arthritis, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016 54
Figure 31: Rheumatoid Arthritis, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2016 55
Figure 32: Rheumatoid Arthritis, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 (part 1) 57
Figure 33: Rheumatoid Arthritis, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 (part 2) 58

【レポートのキーワード】

リウマチ性関節炎治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ リウマチ性関節炎治療薬の世界市場(Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆